Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Booster in Lung Cancer Patients
NCT06168032Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of recurrent symptomatic COVID-19 infection up to 8 weeks. Started Dec 2023; status: recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06168032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168032.